Correction of immune disorders in acute pyelonefritis at different trimesters of pregnancy

The issues of pathogenetic and restorative therapy in gestational pyelonephritis during pregnancy are relevant being discussed in modern evidence-based medicine. Treatment of these patients is associated with certain controversies, since during pregnancy it is necessary not only to provide for relief of the inflammatory process in maternal urinary system, but also not to affect the foetus by the medication applied. This problem is characterized by an annual increase in morbidity and complications, which often have an extremely negative effect on the course of pregnancy and childbirth at the annual rate of 3-17% of women of childbearing age in Russia. The purpose of our study was to determine the effectiveness of using Viferon in stabilizing immune disorders in gestational pyelonephritis. The study included 80 women (mean age 32.4±3.7 years) divided into groups: control (consisting of healthy non-pregnant female volunteers), two groups with acute pyelonephritis in the 2 nd and 3 rd trimesters of pregnancy, receiving basic therapy, and two groups of pregnant women with a combination of basic treatment and the immunomodulator Viferon. The cytokine spectrum, state of the complement system and functional-metabolic activity of neutrophils were studied in peripheral blood. Blood samples were taken before the start of complex treatment, i.e. immediately upon admission, and after the course of therapy (upon discharge from the hospital), with proven evidence of clinical relief of the disease. More effective relief of immune inflammation of acute pyelonephritis was revealed when using Viferon in the 2 nd and 3 rd trimesters of pregnancy compared to conventional therapy. The proposed treatment method allows for faster normalization of altered immune status parameters and the fastest clinical recovery of patients. This approach in medical practice, along with conventional treatment, is a relevant, safe and effective method for treating acute gestational pyelonephritis, which will reduce the incidence of obstetric and urological complications, reduce the number and costs of hospital stays, improve the quality of life of pregnant women and create a healthy environment for the fetal development.